论文部分内容阅读
目的:探讨血清中超氧化物歧酶(SOD)、肿瘤坏死因子(TNF-α)及荧光实时定量PCR(FQ-PCR)检测在婴幼儿支原体肺炎(MPP)早期诊断和治疗中的价值。方法:选择2010年1月~2011年12月肺炎患儿136例,X光检查肺部有明显改变、血清MP抗体4倍及以上滴度升高为MPP患儿,余下为非MPP患儿。分别检测患儿治疗前后的血清SOD、TNF-α浓度及对部分患儿取肺泡灌洗液后进行FQ-PCR;以80份健康儿童血清作为阴性对照。组间率的比较采用χ2检验,计量资料采用t检验,双变量相关分析采用Pearson检验。结果:治疗前MPP患儿血清中SOD和TNF-α浓度均显著高于对照组(P<0.01)。相关分析显示,MP患儿组的血清SOD、TNF-α水平与PCR检测结果呈正相关,对照组的血清水平与PCR检测结果无相关性;治疗后MPP患儿组的SOD和TNF-α浓度水平均显著下降(P<0.01)。结论:联合测定血清中SOD、TNF-α水平及FQ-PCR对MPP患儿的早期诊断、治疗和预后有十分重要的临床价值,可作为评价MPP的转归以及判断临床疗效的指标。
Objective: To investigate the value of serum superoxide dismutase (SOD), tumor necrosis factor (TNF-α) and real-time quantitative PCR (FQ-PCR) in the diagnosis and treatment of infantile mycoplasma pneumonia (MPP). Methods: Thirty-six children with pneumonia were selected from January 2010 to December 2011. The lungs of X-ray examination were significantly changed. The serum MP antibody titer of 4 times or more increased to MPP in children and the rest to non-MPP children. Serum levels of SOD and TNF-α in children before and after treatment were measured, and FQ-PCR was performed after taking alveolar lavage fluid in some children. Serum of 80 healthy children was used as a negative control. Chi-square test was used to compare the rate among groups, t test was used to measure the data, and Pearson test was used to analyze the bivariate correlation. Results: The serum levels of SOD and TNF-α in MPP children before treatment were significantly higher than those in the control group (P <0.01). Correlation analysis showed that there was a positive correlation between the level of serum SOD and TNF-α in serum of MP children and the result of PCR, the serum level of control group had no correlation with the result of PCR. After treatment, the levels of SOD and TNF-α Decreased significantly (P <0.01). Conclusion: The combined determination of serum levels of SOD and TNF-α and FQ-PCR in early diagnosis, treatment and prognosis of MPP patients have very important clinical value, which can be used as an index to evaluate the prognosis of MPP and to judge the clinical efficacy.